Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed
Only 25% of all lung cancers are diagnosed in an early stage allowing surgical treatment. Primary tumours usually concerning lung metastasis are breast, colon, kidney, uterus/cervix, prostate, and head and neck tumours. During recent years many publications have confirmed the effectiveness and relia...
Gespeichert in:
| Veröffentlicht in: | Clinical & translational oncology 2009, Vol.11 (1), p.28-34 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 34 |
|---|---|
| container_issue | 1 |
| container_start_page | 28 |
| container_title | Clinical & translational oncology |
| container_volume | 11 |
| creator | Gómez, Fernando M. Palussière, Jean Santos, Ernesto Tourdias, Thomas Cornélis, François Sáiz, Vicente Montes, Hortensia Eker, Omer |
| description | Only 25% of all lung cancers are diagnosed in an early stage allowing surgical treatment. Primary tumours usually concerning lung metastasis are breast, colon, kidney, uterus/cervix, prostate, and head and neck tumours. During recent years many publications have confirmed the effectiveness and reliability of lung radiofrequency ablation (RFA) alone or together with other techniques (chemotherapy, radiotherapy...). Results suggest that survival increase and curative rates of lung radiofrequency are similar to those achieved by more aggressive procedures and present lower rates of complications. Pneumothorax, pleural effusion and alveolar haemorrhage are the most frequent complications. Indications for lung RFA must be individually evaluated by lung cancer committees. Percutaneous lung RFA may be useful in patients with pulmonary primary tumours and metastases, especially in those with nodules smaller than 3 cm and a peripheral location (>1 cm from the hilum). PET/CT seems to be the most accurate technique in patient follow up. |
| doi_str_mv | 10.1007/s12094-009-0307-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66833086</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66833086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-b97d1457b3d91b410ab31afa28bd496b0558e12a7a11977765f09855ae9f33933</originalsourceid><addsrcrecordid>eNp9kF1LwzAUhoMobk5_gDeSK6_sPKdp2uZShl8wEPxA70LapltH28ykZezfm9GCXnmTk5w8eTl5CLlEmCNAcuswBBEFACIABkkAR2SKsRABA86Pxz1E6deEnDm3Ad-NEU_JBAVyHgJOydurKipTWv3d6zbf026tbWNyo1Z9rbrKtNSUtO7bFe36xvTWzemnRzTdaaqsvqG7Pye61qrQxTk5KVXt9MVYZ-Tj4f598RQsXx6fF3fLIGdR2AWZSAqMeJKxQmAWIaiMoSpVmGZFJOLMT5tqDFWiEEWSJDEvQaScKy1KxgRjM3I95G6t8eO7TjaVy3Vdq1ab3sk4ThmDNPYgDmBujXNWl3Jrq0bZvUSQB5NyMCm9SXkw6ZcZuRrD-6zRxe-LUZ0HwgFw_qpdaSs33k_rP_xP6g8nvX2x</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66833086</pqid></control><display><type>article</type><title>Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Gómez, Fernando M. ; Palussière, Jean ; Santos, Ernesto ; Tourdias, Thomas ; Cornélis, François ; Sáiz, Vicente ; Montes, Hortensia ; Eker, Omer</creator><creatorcontrib>Gómez, Fernando M. ; Palussière, Jean ; Santos, Ernesto ; Tourdias, Thomas ; Cornélis, François ; Sáiz, Vicente ; Montes, Hortensia ; Eker, Omer</creatorcontrib><description>Only 25% of all lung cancers are diagnosed in an early stage allowing surgical treatment. Primary tumours usually concerning lung metastasis are breast, colon, kidney, uterus/cervix, prostate, and head and neck tumours. During recent years many publications have confirmed the effectiveness and reliability of lung radiofrequency ablation (RFA) alone or together with other techniques (chemotherapy, radiotherapy...). Results suggest that survival increase and curative rates of lung radiofrequency are similar to those achieved by more aggressive procedures and present lower rates of complications. Pneumothorax, pleural effusion and alveolar haemorrhage are the most frequent complications. Indications for lung RFA must be individually evaluated by lung cancer committees. Percutaneous lung RFA may be useful in patients with pulmonary primary tumours and metastases, especially in those with nodules smaller than 3 cm and a peripheral location (>1 cm from the hilum). PET/CT seems to be the most accurate technique in patient follow up.</description><identifier>ISSN: 1699-048X</identifier><identifier>EISSN: 1699-3055</identifier><identifier>DOI: 10.1007/s12094-009-0307-0</identifier><identifier>PMID: 19155201</identifier><language>eng</language><publisher>Milan: Springer Milan</publisher><subject>Catheter Ablation - adverse effects ; Catheter Ablation - instrumentation ; Catheter Ablation - methods ; Clinical Trials as Topic ; Humans ; Lung Neoplasms - pathology ; Lung Neoplasms - surgery ; Medicine ; Medicine & Public Health ; Oncology ; Reviews</subject><ispartof>Clinical & translational oncology, 2009, Vol.11 (1), p.28-34</ispartof><rights>Feseo 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-b97d1457b3d91b410ab31afa28bd496b0558e12a7a11977765f09855ae9f33933</citedby><cites>FETCH-LOGICAL-c342t-b97d1457b3d91b410ab31afa28bd496b0558e12a7a11977765f09855ae9f33933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12094-009-0307-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12094-009-0307-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19155201$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez, Fernando M.</creatorcontrib><creatorcontrib>Palussière, Jean</creatorcontrib><creatorcontrib>Santos, Ernesto</creatorcontrib><creatorcontrib>Tourdias, Thomas</creatorcontrib><creatorcontrib>Cornélis, François</creatorcontrib><creatorcontrib>Sáiz, Vicente</creatorcontrib><creatorcontrib>Montes, Hortensia</creatorcontrib><creatorcontrib>Eker, Omer</creatorcontrib><title>Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed</title><title>Clinical & translational oncology</title><addtitle>Clin Transl Oncol</addtitle><addtitle>Clin Transl Oncol</addtitle><description>Only 25% of all lung cancers are diagnosed in an early stage allowing surgical treatment. Primary tumours usually concerning lung metastasis are breast, colon, kidney, uterus/cervix, prostate, and head and neck tumours. During recent years many publications have confirmed the effectiveness and reliability of lung radiofrequency ablation (RFA) alone or together with other techniques (chemotherapy, radiotherapy...). Results suggest that survival increase and curative rates of lung radiofrequency are similar to those achieved by more aggressive procedures and present lower rates of complications. Pneumothorax, pleural effusion and alveolar haemorrhage are the most frequent complications. Indications for lung RFA must be individually evaluated by lung cancer committees. Percutaneous lung RFA may be useful in patients with pulmonary primary tumours and metastases, especially in those with nodules smaller than 3 cm and a peripheral location (>1 cm from the hilum). PET/CT seems to be the most accurate technique in patient follow up.</description><subject>Catheter Ablation - adverse effects</subject><subject>Catheter Ablation - instrumentation</subject><subject>Catheter Ablation - methods</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - surgery</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Reviews</subject><issn>1699-048X</issn><issn>1699-3055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kF1LwzAUhoMobk5_gDeSK6_sPKdp2uZShl8wEPxA70LapltH28ykZezfm9GCXnmTk5w8eTl5CLlEmCNAcuswBBEFACIABkkAR2SKsRABA86Pxz1E6deEnDm3Ad-NEU_JBAVyHgJOydurKipTWv3d6zbf026tbWNyo1Z9rbrKtNSUtO7bFe36xvTWzemnRzTdaaqsvqG7Pye61qrQxTk5KVXt9MVYZ-Tj4f598RQsXx6fF3fLIGdR2AWZSAqMeJKxQmAWIaiMoSpVmGZFJOLMT5tqDFWiEEWSJDEvQaScKy1KxgRjM3I95G6t8eO7TjaVy3Vdq1ab3sk4ThmDNPYgDmBujXNWl3Jrq0bZvUSQB5NyMCm9SXkw6ZcZuRrD-6zRxe-LUZ0HwgFw_qpdaSs33k_rP_xP6g8nvX2x</recordid><startdate>2009</startdate><enddate>2009</enddate><creator>Gómez, Fernando M.</creator><creator>Palussière, Jean</creator><creator>Santos, Ernesto</creator><creator>Tourdias, Thomas</creator><creator>Cornélis, François</creator><creator>Sáiz, Vicente</creator><creator>Montes, Hortensia</creator><creator>Eker, Omer</creator><general>Springer Milan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2009</creationdate><title>Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed</title><author>Gómez, Fernando M. ; Palussière, Jean ; Santos, Ernesto ; Tourdias, Thomas ; Cornélis, François ; Sáiz, Vicente ; Montes, Hortensia ; Eker, Omer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-b97d1457b3d91b410ab31afa28bd496b0558e12a7a11977765f09855ae9f33933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Catheter Ablation - adverse effects</topic><topic>Catheter Ablation - instrumentation</topic><topic>Catheter Ablation - methods</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - surgery</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Reviews</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez, Fernando M.</creatorcontrib><creatorcontrib>Palussière, Jean</creatorcontrib><creatorcontrib>Santos, Ernesto</creatorcontrib><creatorcontrib>Tourdias, Thomas</creatorcontrib><creatorcontrib>Cornélis, François</creatorcontrib><creatorcontrib>Sáiz, Vicente</creatorcontrib><creatorcontrib>Montes, Hortensia</creatorcontrib><creatorcontrib>Eker, Omer</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical & translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez, Fernando M.</au><au>Palussière, Jean</au><au>Santos, Ernesto</au><au>Tourdias, Thomas</au><au>Cornélis, François</au><au>Sáiz, Vicente</au><au>Montes, Hortensia</au><au>Eker, Omer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed</atitle><jtitle>Clinical & translational oncology</jtitle><stitle>Clin Transl Oncol</stitle><addtitle>Clin Transl Oncol</addtitle><date>2009</date><risdate>2009</risdate><volume>11</volume><issue>1</issue><spage>28</spage><epage>34</epage><pages>28-34</pages><issn>1699-048X</issn><eissn>1699-3055</eissn><abstract>Only 25% of all lung cancers are diagnosed in an early stage allowing surgical treatment. Primary tumours usually concerning lung metastasis are breast, colon, kidney, uterus/cervix, prostate, and head and neck tumours. During recent years many publications have confirmed the effectiveness and reliability of lung radiofrequency ablation (RFA) alone or together with other techniques (chemotherapy, radiotherapy...). Results suggest that survival increase and curative rates of lung radiofrequency are similar to those achieved by more aggressive procedures and present lower rates of complications. Pneumothorax, pleural effusion and alveolar haemorrhage are the most frequent complications. Indications for lung RFA must be individually evaluated by lung cancer committees. Percutaneous lung RFA may be useful in patients with pulmonary primary tumours and metastases, especially in those with nodules smaller than 3 cm and a peripheral location (>1 cm from the hilum). PET/CT seems to be the most accurate technique in patient follow up.</abstract><cop>Milan</cop><pub>Springer Milan</pub><pmid>19155201</pmid><doi>10.1007/s12094-009-0307-0</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1699-048X |
| ispartof | Clinical & translational oncology, 2009, Vol.11 (1), p.28-34 |
| issn | 1699-048X 1699-3055 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66833086 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Catheter Ablation - adverse effects Catheter Ablation - instrumentation Catheter Ablation - methods Clinical Trials as Topic Humans Lung Neoplasms - pathology Lung Neoplasms - surgery Medicine Medicine & Public Health Oncology Reviews |
| title | Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T07%3A59%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiofrequency%20thermocoagulation%20of%20lung%20tumours.%20Where%20we%20are,%20where%20we%20are%20headed&rft.jtitle=Clinical%20&%20translational%20oncology&rft.au=G%C3%B3mez,%20Fernando%20M.&rft.date=2009&rft.volume=11&rft.issue=1&rft.spage=28&rft.epage=34&rft.pages=28-34&rft.issn=1699-048X&rft.eissn=1699-3055&rft_id=info:doi/10.1007/s12094-009-0307-0&rft_dat=%3Cproquest_cross%3E66833086%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66833086&rft_id=info:pmid/19155201&rfr_iscdi=true |